A decades-old diabetes drug extends lifespan in a rigorous mouse program — but its human longevity evidence tells a different, more limited story.
Acarbose has been FDA-approved for type 2 diabetes for decades. Its longevity relevance comes from a different program entirely.
Acarbose works by inhibiting alpha-glucosidase enzymes in the small intestine, slowing carbohydrate absorption and blunting post-meal glucose spikes — its approved mechanism for diabetes management. Its longevity-relevant evidence comes from the NIA's Interventions Testing Program (ITP), where it has shown lifespan extension in genetically heterogeneous mice, alongside rapamycin and 17α-estradiol as ITP-validated compounds.
It's worth being precise about what supports acarbose's Moderate evidence tier on Geroevidence. It isn't a single dedicated human longevity trial — it's the combination of an established human RCT base in its approved diabetes indication, plus notable ITP mouse lifespan data. These are two different evidence streams pointing in a complementary direction, not one trial answering the longevity question directly. Gastrointestinal effects — flatulence and bloating in particular — are the most commonly reported side effects from its diabetes-indication trial base.
Acarbose illustrates a pattern that recurs across the longevity pharmacopeia: a drug with decades of approved-indication human safety data, paired with promising but distinct animal longevity data, and no dedicated human trial connecting the two. That gap — not the absence of any evidence — is what the Moderate tier is meant to communicate honestly.